Trial reportEuropean archives of psychiatry and clinical neuroscience2020
Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
Trial report in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Research progress in estrogen as an adjunctive therapy for schizophrenia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Pooled it
- The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.Schizophrenia bulletin · 2023Trial
- The influence of sex on cognition in psychosis.Schizophrenia research. Cognition · 2026Article
- Oestrogen modulators as augmentation to antipsychotics for the treatment of post- and perimenopausal psychosis: a systematic review.Therapeutic advances in psychopharmacology · 2026Review
- 17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats.Molecular psychiatry · 2025Article
- Sex-informed estrogen receptor modulation in schizophrenia: a male-focused ERβ/GPER1 framework for cognitive and negative symptoms.Frontiers in psychiatry · 2025Article
- Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition.Archives of women's mental health · 2024Article
- Estrogen and psychosis - a review and future directions.Archives of women's mental health · 2024Review
- Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.Neuropsychopharmacology reports · 2024Review
- Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.Schizophrenia bulletin open · 2024Article
- The Effect of Menopause on Antipsychotic Response.Brain sciences · 2022Review
- Management of cognitive and negative symptoms in schizophrenia.The mental health clinician · 2022Article
- Hormone Targets for the Treatment of Sleep Disorders in Postmenopausal Women with Schizophrenia: A Narrative Review.Clocks & sleep · 2022Review
- Estrogen, Cognitive Performance, and Functional Imaging Studies: What Are We Missing About Neuroprotection?Frontiers in cellular neuroscience · 2022Review
- Peri- and Post-Menopausal Women with Schizophrenia and Related Disorders Are a Population with Specific Needs: A Narrative Review of Current Theories.Journal of personalized medicine · 2021Review
- Estrogens in schizophrenia: progress, current challenges and opportunities.Current opinion in psychiatry · 2021Review
- The Role of Estrogen Receptors and Their Signaling across Psychiatric Disorders.International journal of molecular sciences · 2020Review
- Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol.Contemporary clinical trials communications · 2020Article
- Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes.International journal of environmental research and public health · 2020Review
- Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed.World journal of psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
We assessed the utility of raloxifene (60 mg/day) as an adjuvant treatment for cognitive symptoms in postmenopausal women with schizophrenia in a 24-week, double-blind, randomized, placebo-controlled study. Patients were recruited from the inpatient and outpatient services of Parc Sanitari Sant Joan de Déu, Hospital Universitari Institut Pere Mata, and Corporació Sanitària Parc Taulí. Seventy eight postmenopausal women with schizophrenia were randomized to either adjunctive raloxifene or placebo. Sixty-eight began the clinical trial (37 women on raloxifene adjunct) and 31 on placebo adjunct. The outcome measures were: memory, attention and executive function. Assessment was conducted at baseline and at week 24. Between groups homogeneity was tested with the Student's t test for continuous variables and/or the Mann-Whitney U test for ordinal variables and the χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.